SCOTUS Keeps Deadly Abortion Pill on the Market

Tierin-Rose Mandelburg | April 24, 2023
Text Audio
00:00 00:00
Font Size

Last week, less than a year after the U.S. Supreme Court overturned Roe v. Wade, the court debated the decades-long decision of the FDA to approve a chemical abortion drug called mifepristone for sale at retail pharmacies. Unfortunately, despite the FDA’s inadequate research, the Supreme Court ruled to keep mifepristone on the market. 

The news of this is shocking and heartbreaking for those in the pro-life movement. 

Prior to the announcement, numerous pro-lifers were prayerfully hoping the deadly drug would be pulled.

The fact of the matter is that mifepristone is an extremely harmful drug. On top of the fact that it ends at least one life - the life of the child in the womb - it also poses significant threats to the health and even life of the mother. Mifepristone, the first of a two-pill abortion-inducing regimen, chemically kills an unborn baby and can cause the mother to experience up to a month of cramping, bleeding and severe pain. As a matter of fact, the drug is “four times more dangerous” than surgical abortions and has reportedly increased abortion-related ER visits by 500 percent from 2002-2015, according to Republican Sen. James Lankford's office.

Related: FDA Sued Over Dangerous Abortion Drug

The FDA back in March was sued by eight individuals who said they had witnessed the damaging effects of the drug. Represented by Alliance Defending Freedom, the group condemned the negligence of the FDA and said it should be “illegal” to distribute such a harmful and dangerous drug. 

Even still, Friday's news that the Supreme Court decided to keep the drug legal and available shows just how pro-abortion our nation has become. These people aren't pro-woman, they're pro baby death, as evidenced by many of the people who fought to keep the deadly pill on the market.

It’s a shame what lengths our so-called "leaders" will go to ensure that babies can be slaughtered easily and frequently. 

Follow us on Twitter: